IASLC Tumor Budding Grade Flags High-Risk Resected Lung Squamous Cell Carcinoma Patients

A new tumor‑budding–based grading system proposed by the International Association for the Study of Lung Cancer (IASLC) has shown promise in identifying patients with resected lung squamous cell carcinoma (SqCC) who are at higher risk of poor outcomes. The findings were presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) and suggest that the grading system could help clinicians determine which patients may benefit most from adjuvant chemotherapy after surgery.

In the study, pathologists evaluated tumor budding—small clusters of cancer cells at the invasive front of tumors—across a cohort of resected SqCC specimens. Patients whose tumors exhibited a higher degree of budding had significantly lower overall survival and disease‑free survival rates compared with those with lower budding scores. The grading system, which incorporates quantitative budding assessment, demonstrated a strong correlation with established prognostic markers and provided additional risk stratification beyond conventional staging.

If validated in larger, prospective trials, the IASLC tumor‑budding grading system could become a useful tool in clinical decision‑making, enabling more personalized adjuvant treatment plans for lung SqCC patients. The IASLC conference highlighted the potential of this approach to refine risk assessment and improve outcomes for a patient group that historically has limited therapeutic options after surgery.